Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death.

PURPOSE To analyze the available data concerning mechanisms of action of and mechanisms of resistance to the antitubulin agents, vinca alkaloids and taxanes, and more recently described compounds. DESIGN We conducted a review of the literature on classic and recent antitubulin agents, focusing particularly on the relationships between antitubulin agents and their intracellular target, the soluble tubulin/microtubule complex. RESULTS AND CONCLUSION Although it is widely accepted that antitubulin agents block cell division by inhibition of the mitotic spindle, the mechanism of action of antitubulin agents on microtubules remains to be determined. The classic approach is that vinca alkaloids depolymerize microtubules, thereby increasing the soluble tubulin pool, whereas taxanes stabilize microtubules and increase the microtubular mass. More recent data suggest that both classes of agents have a similar mechanism of action, involving the inhibition of microtubule dynamics. These data suggest that vinca alkaloids and taxanes may act synergistically as antitumor agents and may be administered as combination chemotherapy in the clinic. However, enhanced myeloid and neurologic toxicity, as well as a strong dependence on the sequence of administration, presently exclude these combinations outside the context of clinical trials. Although the multidrug resistance phenotype mediated by Pgp appears to be an important mechanism of resistance to these agents, alterations of microtubule structure resulting in altered microtubule dynamics and/or altered binding of antitubulin agents may constitute a significant mechanism of drug resistance.

[1]  G. Millot,et al.  Estramustine resistance correlates with tau over‐expression in human prostatic carcinoma cells , 1998, International journal of cancer.

[2]  V. Georgoulias,et al.  Salvage chemotherapy with paclitaxel, vinorelbine, and cisplatin (PVC) in anthracycline-resistant advanced breast cancer. , 1998, American journal of clinical oncology.

[3]  D. Braguer,et al.  Effect of microtubule disruption on cell adhesion and spreading. , 1998, Biochemical and biophysical research communications.

[4]  F. Fitzpatrick,et al.  Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[5]  A. Levine,et al.  The role of MAP4 expression in the sensitivity to paclitaxel and resistance to vinca alkaloids in p53 mutant cells , 1998, Oncogene.

[6]  M. Jordan,et al.  Microtubules and actin filaments: dynamic targets for cancer chemotherapy. , 1998, Current opinion in cell biology.

[7]  C. Stein,et al.  Taxol and estramustine-induced modulation of human prostate cancer cell apoptosis via alteration in bcl-xL and bak expression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  G L Rosner,et al.  Modulation of vinblastine resistance in metastatic renal cell carcinoma with cyclosporine A or tamoxifen: a cancer and leukemia group B study. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  R. Himes,et al.  Mechanism of action of the unusually potent microtubule inhibitor cryptophycin 1. , 1997, Biochemistry.

[10]  M. Kavallaris,et al.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.

[11]  P. Fumoleau,et al.  Docetaxel in combination with doxorubicin or vinorelbine. , 1997, European journal of cancer.

[12]  V. Miller Docetaxel (Taxotere) and vinorelbine in the treatment of advanced non-small cell lung cancer: preliminary results of a phase I/II trial. , 1997, Seminars in oncology.

[13]  T. Fojo,et al.  Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization* , 1997, The Journal of Biological Chemistry.

[14]  W. B. Derry,et al.  Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. , 1997, Biochemistry.

[15]  A. Photiou,et al.  In vitro synergy of paclitaxel (Taxol) and vinorelbine (navelbine) against human melanoma cell lines. , 1997, European journal of cancer.

[16]  K. Tew,et al.  Interaction of estramustine with tubulin isotypes. , 1997, Biochemistry.

[17]  J. Bulinski,et al.  Overexpression of full- or partial-length MAP4 stabilizes microtubules and alters cell growth. , 1997, Journal of cell science.

[18]  A. Levine,et al.  Wild-type p53 negatively regulates the expression of a microtubule-associated protein. , 1996, Genes & development.

[19]  R. Flavell,et al.  Double knockout of the MRP gene leads to increased drug sensitivity in vitro. , 1996, Cancer research.

[20]  G. Viale,et al.  The microtubule-affecting drug paclitaxel has antiangiogenic activity. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  T. Fojo,et al.  Paclitaxel (Taxol(R)) inhibits motility of paclitaxel-resistant human ovarian carcinoma cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  F. Muggia,et al.  Severe neurotoxicity from vinorelbine-paclitaxel combinations. , 1996, Journal of the National Cancer Institute.

[23]  Christophe Ampe,et al.  Pathway Leading to Correctly Folded β-Tubulin , 1996, Cell.

[24]  K. Tew,et al.  Increase of βIII- and βIVa-Tubulin Isotypes in Human Prostate Carcinoma Cells as a Result of Estramustine Resistance , 1996 .

[25]  W. B. Derry,et al.  Mitotic block induced in HeLa cells by low concentrations of paclitaxel (Taxol) results in abnormal mitotic exit and apoptotic cell death. , 1996, Cancer research.

[26]  G. Demers,et al.  Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. , 1996, Cancer research.

[27]  H. Rosenkranz,et al.  Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. , 1996, Biochemistry.

[28]  M. Haber,et al.  Altered Expression of M2, the Class II -Tubulin Isotype, in a Murine J774.2 Cell Line with a High Level of Taxol Resistance (*) , 1995, The Journal of Biological Chemistry.

[29]  R. Tishler,et al.  Microtubule-active drugs taxol, vinblastine, and nocodazole increase the levels of transcriptionally active p53. , 1995, Cancer research.

[30]  L. Neckers,et al.  Taxol induction of p21WAF1 and p53 requires c-raf-1. , 1995, Cancer research.

[31]  D. Brown,et al.  Effects of taxol on the polymerization and posttranslational modification of class III beta-tubulin in P19 embryonal carcinoma cells. , 1995, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[32]  P. Wadsworth,et al.  Vinblastine suppresses dynamics of individual microtubules in living interphase cells. , 1995, Molecular biology of the cell.

[33]  M. Jordan,et al.  Microtubule dynamics: taking aim at a moving target. , 1995, Chemistry & biology.

[34]  F. Kaye,et al.  The N-terminal domain of c-Myc associates with alpha-tubulin and microtubules in vivo and in vitro , 1995, Molecular and cellular biology.

[35]  C. Miller,et al.  Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells. , 1995, Journal of the National Cancer Institute.

[36]  E. Lazarides,et al.  Taxol-Induced Mitotic Block Triggers Rapid Onset of a p53-Independent Apoptotic Pathway , 1995, Molecular medicine.

[37]  A. Frankfurter,et al.  Binding of vinblastine to phosphocellulose-purified and alpha beta-class III tubulin: the role of nucleotides and beta-tubulin isotypes. , 1995, Biochemistry.

[38]  M. Clarke,et al.  Overexpression of Bcl-XS sensitizes MCF-7 cells to chemotherapy-induced apoptosis. , 1995, Cancer research.

[39]  R. Maccioni,et al.  Identification of a new microtubule-interacting protein Mip-90. , 1995, European Journal of Cell Biology.

[40]  E. Lazarides,et al.  Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. , 1995, Cancer research.

[41]  E. Hamel,et al.  Interaction of dolastatin 10 with tubulin: induction of aggregation and binding and dissociation reactions. , 1995, Molecular pharmacology.

[42]  M. Abeloff Vinorelbine (Navelbine) in the treatment of breast cancer: a summary. , 1995, Seminars in oncology.

[43]  W. B. Derry,et al.  Substoichiometric binding of taxol suppresses microtubule dynamics. , 1995, Biochemistry.

[44]  J. Forrest,et al.  Protein kinase C zeta is associated with the mitotic apparatus in primary cell cultures of the shark rectal gland. , 1994, The Journal of biological chemistry.

[45]  D. Panda,et al.  Microtubule dynamics in vitro are regulated by the tubulin isotype composition. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[46]  G. M. Wilson,et al.  Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. , 1994, Cancer research.

[47]  A. Santoro,et al.  Vinorelbine: an active drug for the management of patients with heavily pretreated Hodgkin's disease. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.

[48]  C. Coltman Vinorelbine (Navelbine)--a new agent for the treatment of non-small cell lung cancer: a summary. , 1994, Seminars in oncology.

[49]  H. Hotani,et al.  Microtubule-stabilizing activity of microtubule-associated proteins (MAPs) is due to increase in frequency of rescue in dynamic instability: shortening length decreases with binding of MAPs onto microtubules. , 1994, Cell structure and function.

[50]  D. Golan,et al.  Microtubule inhibitors differentially affect translational movement, cell surface expression, and endocytosis of transferrin receptors in K562 cells , 1994, Journal of cellular physiology.

[51]  C. Smith,et al.  Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. , 1994, Cancer research.

[52]  C. Mioskowski,et al.  Predominant labeling of beta- over alpha-tubulin from porcine brain by a photoactivatable taxoid derivative. , 1994, Biochemistry.

[53]  M. Jordan,et al.  Removal of the projection domain of microtubule-associated protein 2 alters its interaction with tubulin , 1994, Journal of protein chemistry.

[54]  I. Ringel,et al.  3'-(p-azidobenzamido)taxol photolabels the N-terminal 31 amino acids of beta-tubulin. , 1994, The Journal of biological chemistry.

[55]  M. Jordan,et al.  Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[56]  T. Kishimoto,et al.  Association of p34cdc2/cyclin B complex with microtubules in starfish oocytes. , 1993, Journal of cell science.

[57]  S. Hahn,et al.  Glutathione depletion by L-buthionine sulfoximine antagonizes taxol cytotoxicity. , 1993, Cancer research.

[58]  R. Williams,et al.  Taxol-induced flexibility of microtubules and its reversal by MAP-2 and Tau. , 1993, The Journal of biological chemistry.

[59]  B. Coiffier,et al.  Long-term outcome and sequelae in aggressive lymphoma patients treated with the LNH-80 regimen. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[60]  K. Tew,et al.  Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. , 1992, Cancer research.

[61]  M. Jordan,et al.  Effects of vinblastine, podophyllotoxin and nocodazole on mitotic spindles. Implications for the role of microtubule dynamics in mitosis. , 1992, Journal of cell science.

[62]  V. Ling P‐glycoprotein and resistance to anticancer drugs , 1992 .

[63]  Yixian Zheng,et al.  γ-Tubulin is present in Drosophila melanogaster and homo sapiens and is associated with the centrosome , 1991, Cell.

[64]  M. Jordan,et al.  Mechanism of inhibition of cell proliferation by Vinca alkaloids. , 1991, Cancer research.

[65]  S. Barlow,et al.  Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. , 1991, The Journal of biological chemistry.

[66]  A. Newland,et al.  INFUSION OF VINCRISTINE AND DOXORUBICIN WITH ORAL DEXAMETHASONE AS FIRST-LINE THERAPY FOR MULTIPLE MYELOMA , 1989, The Lancet.

[67]  S. Barlow,et al.  Mechanisms by which mammalian cells acquire resistance to drugs that affect microtubule assembly , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  S. Barlow,et al.  Elimination of permeability mutants from selections for drug resistance in mammalian cells , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[69]  D. Cleveland,et al.  In vivo microtubules are copolymers of available beta-tubulin isotypes: localization of each of six vertebrate beta-tubulin isotypes using polyclonal antibodies elicited by synthetic peptide antigens , 1987, The Journal of cell biology.

[70]  W. Gu,et al.  Free intermingling of mammalian β-tubulin isotypes among functionally distinct microtubules , 1987, Cell.

[71]  I. Pastan,et al.  Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Paul R. Dobner,et al.  Alternative 5' exons either provide or deny an initiator methionine codon to the same alpha-tubulin coding region , 1987, Nucleic Acids Res..

[73]  A. Villasanté,et al.  Six mouse alpha-tubulin mRNAs encode five distinct isotypes: testis-specific expression of two sister genes , 1986, Molecular and cellular biology.

[74]  K. Sullivan,et al.  Identification of conserved isotype-defining variable region sequences for four vertebrate beta tubulin polypeptide classes. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[75]  C. Spurr,et al.  Single agent vincristine by infusion in refractory multiple myeloma. , 1985, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  B I Sikic,et al.  Multidrug (pleiotropic) resistance in doxorubicin-selected variants of the human sarcoma cell line MES-SA. , 1985, Cancer research.

[77]  I. Maclennan,et al.  Objective evaluation of the role of vincristine in induction and maintenance therapy for myelomatosis. Medical Research Council Working Party on Leukaemia in Adults. , 1985, British Journal of Cancer.

[78]  M. Jordan,et al.  Interaction of reduced glutathione with bovine brain tubulin. , 1985, Biochemical and biophysical research communications.

[79]  J. Hall,et al.  Three expressed sequences within the human beta-tubulin multigene family each define a distinct isotype. , 1985, Journal of molecular biology.

[80]  M. Kirschner,et al.  A polymer-dependent increase in phosphorylation of beta-tubulin accompanies differentiation of a mouse neuroblastoma cell line , 1985, The Journal of cell biology.

[81]  M. Kirschner,et al.  Dynamic instability of microtubule growth , 1984, Nature.

[82]  K. Farrell,et al.  Tubulin-colchicine complexes differentially poison opposite microtubule ends. , 1984, Biochemistry.

[83]  J. Riordan,et al.  Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. , 1983, Science.

[84]  P. Binkley,et al.  beta 2-Tubulin, a form of chordate brain tubulin with lesser reactivity toward an assembly-inhibiting sulfhydryl-directed cross-linking reagent. , 1982, Biochemistry.

[85]  F. Malkinson Colchicine. New uses of an old, old drug. , 1982, Archives of dermatology.

[86]  M. G. Lee,et al.  Evidence that a human β-tubulin pseudogene is derived from its corresponding mRNA , 1982, Nature.

[87]  J Parness,et al.  Taxol binds to polymerized tubulin in vitro , 1981, The Journal of cell biology.

[88]  M. Gottesman,et al.  Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in alpha-tubulin. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[89]  M. Gottesman,et al.  CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin , 1980, Cell.

[90]  R. Margolis,et al.  Opposite end assembly and disassembly of microtubules at steady state in vitro , 1978, Cell.

[91]  M. Kirschner,et al.  Purification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. , 1977, Journal of molecular biology.

[92]  I. Meza,et al.  THE MECHANISM OF ACTION OF COLCHICINE , 1973, The Journal of cell biology.

[93]  E. Nogales,et al.  Structure of the alpha beta tubulin dimer by electron crystallography. , 1998, Nature.

[94]  R. Luduena Multiple forms of tubulin: different gene products and covalent modifications. , 1998, International review of cytology.

[95]  G. Demers,et al.  Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.

[96]  J Vandekerckhove,et al.  Pathway leading to correctly folded beta-tubulin. , 1996, Cell.

[97]  B. Sikic,et al.  Novel mechanism of resistance to paclitaxel (Taxol) in human K562 leukemia cells by combined selection with PSC 833. , 1995, Oncology research.

[98]  J. Reed,et al.  High levels of p26BCL-2 oncoprotein retard taxol-induced apoptosis in human pre-B leukemia cells. , 1994, Leukemia.

[99]  T. Mitchison,et al.  Dynamics of microtubule assembly in vivo , 1994 .

[100]  C. Echeverri,et al.  Differential sorting of beta tubulin isotypes into colchicine-stable microtubules during neuronal and muscle differentiation of embryonal carcinoma cells. , 1992, Cell motility and the cytoskeleton.

[101]  E. Hamel Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B. , 1992, Pharmacology & therapeutics.

[102]  V. Ling Charles F. Kettering Prize. P-glycoprotein and resistance to anticancer drugs. , 1992, Cancer.

[103]  S B Hastie,et al.  Interactions of colchicine with tubulin. , 1991, Pharmacology & therapeutics.

[104]  C. Keith,et al.  Neurite elongation is blocked if microtubule polymerization is inhibited in PC12 cells. , 1990, Cell motility and the cytoskeleton.

[105]  M. Little,et al.  Comparative analysis of tubulin sequences. , 1988, Comparative biochemistry and physiology. B, Comparative biochemistry.

[106]  M. Kirschner Microtubule assembly and nucleation. , 1978, International review of cytology.